Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.

Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson LA, Llovet JM, Finn RS, Groopman JD, El-Serag HB, Monga SP, Wang XW, Karin M, Schwartz RE, Tanabe KK, Roberts LR, Gunaratne PH, Tsung A, Brown KA, Lawrence TS, Salem R, Singal AG, Kim AK, Rabiee A, Resar L, Hoshida Y, He AR, Ghoshal K, Ryan PB, Jaffee EM, Guha C, Mishra L, Coleman CN, Ahmed MM.

Cancer Res. 2019 Sep 1;79(17):4326-4330. doi: 10.1158/0008-5472.CAN-19-0803.

PMID:
31481419
2.

Weakness and Myalgia in a Patient With Hepatocellular Carcinoma Undergoing Checkpoint Inhibitor Therapy.

Shah PP, Romo CG, Yarchoan M.

JAMA Oncol. 2019 Aug 29. doi: 10.1001/jamaoncol.2019.2304. [Epub ahead of print] No abstract available.

PMID:
31465106
3.

Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma.

Jafarnejad M, Sové RJ, Danilova L, Mirando AC, Zhang Y, Yarchoan M, Tran PT, Pandey NB, Fertig EJ, Popel AS.

NPJ Syst Biol Appl. 2019 Aug 16;5:29. doi: 10.1038/s41540-019-0107-2. eCollection 2019.

4.

Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.

Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, Zimmerman JW, Hajjir K, Venkatraman D, Armstrong DK, Laheru DA, Mehra R, Ho WJ, Reuss JE, Heng J, Vellanki P, Donehower RC, Holdhoff M, Naidoo J.

J Oncol Pract. 2019 Sep;15(9):e825-e834. doi: 10.1200/JOP.18.00703. Epub 2019 Aug 6.

PMID:
31386608
5.

Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.

Danilova L, Ho WJ, Zhu Q, Vithayathil T, De Jesus-Acosta A, Azad NS, Laheru DA, Fertig EJ, Anders R, Jaffee EM, Yarchoan M.

Cancer Immunol Res. 2019 Jun;7(6):886-895. doi: 10.1158/2326-6066.CIR-18-0822. Epub 2019 May 1.

PMID:
31043417
6.

Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma.

Kim AK, Gani F, Layman AJ, Besharati S, Zhu Q, Succaria F, Engle EL, Bhaijee F, Goggins MB, Llosa NJ, Pawlik TM, Yarchoan M, Jaffee EM, Simons HC, Taube JM, Anders RA.

Cancer Immunol Res. 2019 May;7(5):805-812. doi: 10.1158/2326-6066.CIR-18-0499. Epub 2019 Mar 22.

PMID:
30902819
7.

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.

Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, Zaidi N, Azad NS, Laheru DA, Frampton GM, Jaffee EM.

JCI Insight. 2019 Mar 21;4(6). pii: 126908. doi: 10.1172/jci.insight.126908. eCollection 2019 Mar 21.

8.

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.

Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE.

Am J Hematol. 2019 May;94(5):563-574. doi: 10.1002/ajh.25448. Epub 2019 Mar 13.

PMID:
30790338
9.

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S.

Ann Oncol. 2019 Jan 1;30(1):44-56. doi: 10.1093/annonc/mdy495.

10.

Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.

Kinkead HL, Hopkins A, Lutz E, Wu AA, Yarchoan M, Cruz K, Woolman S, Vithayathil T, Glickman LH, Ndubaku CO, McWhirter SM, Dubensky TW Jr, Armstrong TD, Jaffee EM, Zaidi N.

JCI Insight. 2018 Oct 18;3(20). pii: 122857. doi: 10.1172/jci.insight.122857.

11.

Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas.

Ho WJ, Yarchoan M, Hopkins A, Mehra R, Grossman S, Kang H.

J Immunother Cancer. 2018 Aug 31;6(1):84. doi: 10.1186/s40425-018-0395-x.

12.

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.

Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, Laheru DA, Le DT, Lutz ER, Jaffee EM.

JCI Insight. 2018 Jul 12;3(13). pii: 122092. doi: 10.1172/jci.insight.122092.

13.

Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis.

Deshwar AB, Sugar E, Torto D, De Jesus-Acosta A, Weiss MJ, Wolfgang CL, Le D, He J, Burkhart R, Zheng L, Laheru D, Yarchoan M.

Ann Pancreat Cancer. 2018;1. pii: 13. doi: 10.21037/apc.2018.02.01. Epub 2018 Feb 27.

14.

Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis.

Adler BL, Pezhouh MK, Kim A, Luan L, Zhu Q, Gani F, Yarchoan M, Chen J, Voltaggio L, Parian A, Lazarev M, Lauwers GY, Pawlik TM, Montgomery EA, Jaffee E, Le DT, Taube JM, Anders RA.

J Intern Med. 2018 Jun;283(6):568-577. doi: 10.1111/joim.12744. Epub 2018 Mar 24.

15.

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.

Diehl A, Yarchoan M, Hopkins A, Jaffee E, Grossman SA.

Oncotarget. 2017 Dec 14;8(69):114268-114280. doi: 10.18632/oncotarget.23217. eCollection 2017 Dec 26.

16.

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.

Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, Zinner R, Azad NS.

Br J Cancer. 2018 Jan;118(2):e2. doi: 10.1038/bjc.2017.418. Epub 2018 Jan 9. No abstract available.

17.

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Yarchoan M, Hopkins A, Jaffee EM.

N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444. No abstract available.

18.

Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.

Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, Popovic A, Pawlik TM, Kim AK, Zhu Q, Jaffee EM, Taube JM, Anders RA.

Clin Cancer Res. 2017 Dec 1;23(23):7333-7339. doi: 10.1158/1078-0432.CCR-17-0950. Epub 2017 Sep 19.

19.

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.

Anagnostou V, Yarchoan M, Hansen AR, Wang H, Verde F, Sharon E, Collyar D, Chow LQM, Forde PM.

Clin Cancer Res. 2017 Sep 1;23(17):4959-4969. doi: 10.1158/1078-0432.CCR-16-3065.

20.

Targeting neoantigens to augment antitumour immunity.

Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM.

Nat Rev Cancer. 2017 Aug 24;17(9):569. doi: 10.1038/nrc.2017.74. No abstract available.

PMID:
28835723
21.

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.

Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M.

Oncotarget. 2017 Jul 4;8(27):44073-44081. doi: 10.18632/oncotarget.17237.

22.

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.

Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, Zinner R, Azad NS.

Br J Cancer. 2017 May 23;116(11):1402-1407. doi: 10.1038/bjc.2017.119. Epub 2017 Apr 25. Erratum in: Br J Cancer. 2018 Jan 09;:.

23.

Strategies for Increasing Pancreatic Tumor Immunogenicity.

Johnson BA 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM.

Clin Cancer Res. 2017 Apr 1;23(7):1656-1669. doi: 10.1158/1078-0432.CCR-16-2318. Review.

24.

Targeting neoantigens to augment antitumour immunity.

Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM.

Nat Rev Cancer. 2017 Apr;17(4):209-222. doi: 10.1038/nrc.2016.154. Epub 2017 Feb 24. Review. Erratum in: Nat Rev Cancer. 2017 Aug 24;17 (9):569.

25.

Association of Cancer History with Alzheimer's Disease Dementia and Neuropathology.

Yarchoan M, James BD, Shah RC, Arvanitakis Z, Wilson RS, Schneider J, Bennett DA, Arnold SE.

J Alzheimers Dis. 2017;56(2):699-706. doi: 10.3233/JAD-160977.

26.

Ipilimumab-Induced Enteritis without Colitis: A New Challenge.

Messmer M, Upreti S, Tarabishy Y, Mazumder N, Chowdhury R, Yarchoan M, Holdhoff M.

Case Rep Oncol. 2016 Nov 8;9(3):705-713. eCollection 2016 Sep-Dec.

27.

pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.

Yarchoan M, Ma C, Troxel AB, Stopenski SJ, Tang W, Cohen AB, Pappas-Paxinos M, Johnson BA 3rd, Chen EY, Feldman MD, Brose MS.

Horm Cancer. 2016 Jun;7(3):188-95. doi: 10.1007/s12672-016-0253-6. Epub 2016 Mar 18.

PMID:
26994002
28.

Oligometastatic Adenocarcinoma of the Lung: A Therapeutic Opportunity for Long-Term Survival.

Yarchoan M, Lim M, Brahmer JR, Ettinger D.

Cureus. 2015 Dec 16;7(12):e409. doi: 10.7759/cureus.409.

29.

Reply to C. Bal et al and M. Xing.

Yarchoan M, LiVolsi VA, Brose MS.

J Clin Oncol. 2015 Aug 1;33(22):2483. doi: 10.1200/JCO.2015.61.4859. Epub 2015 Jun 29. No abstract available.

PMID:
26124481
30.

BRAF mutation and thyroid cancer recurrence.

Yarchoan M, LiVolsi VA, Brose MS.

J Clin Oncol. 2015 Jan 1;33(1):7-8. doi: 10.1200/JCO.2014.59.3657. Epub 2014 Nov 24. No abstract available.

PMID:
25422487
31.

Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies.

Yarchoan M, Toledo JB, Lee EB, Arvanitakis Z, Kazi H, Han LY, Louneva N, Lee VM, Kim SF, Trojanowski JQ, Arnold SE.

Acta Neuropathol. 2014 Nov;128(5):679-89. doi: 10.1007/s00401-014-1328-5. Epub 2014 Aug 9.

32.

Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease.

Yarchoan M, Arnold SE.

Diabetes. 2014 Jul;63(7):2253-61. doi: 10.2337/db14-0287. Epub 2014 Jun 15. Review.

33.

Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition.

Adler BL, Yarchoan M, Hwang HM, Louneva N, Blair JA, Palm R, Smith MA, Lee HG, Arnold SE, Casadesus G.

Neurobiol Aging. 2014 Apr;35(4):793-801. doi: 10.1016/j.neurobiolaging.2013.10.076. Epub 2013 Oct 11.

PMID:
24239383
34.

Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease.

Yarchoan M, Louneva N, Xie SX, Swenson FJ, Hu W, Soares H, Trojanowski JQ, Lee VM, Kling MA, Shaw LM, Chen-Plotkin A, Wolk DA, Arnold SE.

J Neurol Sci. 2013 Oct 15;333(1-2):9-12. doi: 10.1016/j.jns.2013.05.028. Epub 2013 Aug 23.

35.

Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias.

Yarchoan M, Xie SX, Kling MA, Toledo JB, Wolk DA, Lee EB, Van Deerlin V, Lee VM, Trojanowski JQ, Arnold SE.

Brain. 2012 Dec;135(Pt 12):3749-56. doi: 10.1093/brain/aws271. Epub 2012 Nov 30.

36.

Duplex ultrasound imaging to detect limb stenosis or kinking of endovascular device.

Blom AS, Troutman D, Beeman B, Yarchoan M, Dougherty MJ, Calligaro KD.

J Vasc Surg. 2012 Jun;55(6):1577-80. doi: 10.1016/j.jvs.2011.12.058. Epub 2012 Feb 16.

37.

Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice.

Bish LT, Yarchoan M, Sleeper MM, Gazzara JA, Morine KJ, Acosta P, Barton ER, Sweeney HL.

PLoS One. 2011;6(6):e20856. doi: 10.1371/journal.pone.0020856. Epub 2011 Jun 22.

38.

Who will manage American patients with diabetes? Residents' career preferences and perceptions of diabetes care.

Yarchoan M, Dougan ML, Tjota MY, Milliner BH, Adler BL, Armah KA, Gooley TA, Close KL, Close J, Hirsch IB.

Endocr Pract. 2011 Mar-Apr;17(2):235-9. doi: 10.4158/EP10250.OR.

PMID:
21041164

Supplemental Content

Loading ...
Support Center